PubRank
Search
About
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Clinical Trial ID NCT02089685
PubWeight™ 14.47
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT02089685
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Clin Cancer Res
2018
1.38
2
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Oncoimmunology
2015
1.06
3
Pembrolizumab.
J Immunother Cancer
2015
0.99
4
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
J Clin Invest
2015
0.98
5
Trial watch: Immunostimulatory cytokines in cancer therapy.
Oncoimmunology
2014
0.95
6
Updates in Therapy for Advanced Melanoma.
Cancers (Basel)
2016
0.91
7
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Cancer J
2014
0.88
8
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.
Ther Adv Urol
2015
0.88
9
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
Onco Targets Ther
2014
0.85
10
The past, present and future of immunotherapy against tumor.
Transl Lung Cancer Res
2015
0.85
11
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Biomed Res Int
2015
0.83
12
Advances in immunotherapy for melanoma.
BMC Med
2016
0.83
13
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
14
Pembrolizumab for the treatment of advanced melanoma.
Expert Opin Orphan Drugs
2016
0.80
15
Immunobiology and immunotherapy in genitourinary malignancies.
Ann Transl Med
2016
0.78
16
Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.
Urol Oncol
2015
0.78
17
Trial Watch-Immunostimulation with cytokines in cancer therapy.
Oncoimmunology
2015
0.77
18
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
BioDrugs
2014
0.76
Next 100